Brief: Aurinia Pharmaceuticals Announces Nice Recommendation Of Lupkynis For Adults With Active Lupus Nephritis
03/05/2023 12:57
May 3 (Reuters) - Aurinia Pharmaceuticals Inc AUPH.O :
* AURINIA PHARMACEUTICALS ANNOUNCES NICE RECOMMENDATION OF
LUPKYNIS® (VOCLOSPORIN) FOR ADULTS WITH ACTIVE LUPUS NEPHRITIS
Source text for Eikon: ID:nBw5fBLjla
Further company coverage: AUPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aurinia Pharmaceuticals
See all newsBrief: Aurinia Settles Patent Litigation With Teva
Canada's Aurinia Q2 revenue rises on LUPKYNIS sales
Brief: Aurinia Pharmaceuticals Q2 Pretax Profit USD 48.786 Million
Aurinia Pharmaceuticals Inc expected to post earnings of 24 cents a share - Earnings Preview
Brief: Lupkynis Associated With A Statistically Significant 53% Reduction In Risk Of Renal-Related Event Or Death